Lumacaftor Completed Phase 3 Trials for Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01931839A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis